Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-label, Single-arm，Multicenter Study of F520 in Patients With Urothelial Carcinoma

NCT04636515 is registered in ClinicalTrials.gov with Shandong New Time Pharmaceutical Co., LTD as lead sponsor.

NCT NCT04636515
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04636515 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-label, Single-arm，Multicenter Study of F520 in Patients With Urothelial Carcinoma
Lead sponsor
Shandong New Time Pharmaceutical Co., LTD
Phase
Phase 2
Overall status
Unknown status
Start date
January 31, 2021
Completion date
September 30, 2022
Enrollment
80 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced or metastatic urothelial cell carcinoma